JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
Int J Impot Res
; 18(5): 477-83, 2006.
Article
in En
| MEDLINE
| ID: mdl-16528290
ABSTRACT
Phosphodiesterase 5 (PDE5) inhibitors are efficacious in treating patients with erectile dysfunction. New PDE5 inhibitors with different selectivity and pharmacokinetic profiles have been vigorously pursued. Here we report two novel, potent, and selective PDE5 inhibitors, JNJ-10280205 and JNJ-10287069, with Ki values of 0.05 and 0.12 nM, respectively. Both compounds displayed superior selectivity against PDE1-4 and -6 when compared to sildenafil. In the anesthetized dogs, JNJ-10280205 and JNJ-10287069 exhibited similar efficacy as sildenafil in enhancing erectile functions, with no significant effect on cardiovascular parameters. Pharmacokinetic studies showed that JNJ-10287069 had better oral bioavailability than JNJ-10280205 in several animal species. In vitro study suggested that cytochrome P450 (CYP) 3A4 played a major role in the metabolism of both compounds. The compounds inhibited some of the CYP450 enzymes and the human ether-a-go-go (HERG) channel at much higher concentrations than that required to inhibit PDE5, thus, no cross inhibition would be expected at therapeutic doses. Both compounds are suitable clinical candidates.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
3',5'-Cyclic-GMP Phosphodiesterases
/
Quinolones
/
Enzyme Inhibitors
/
Erectile Dysfunction
Limits:
Animals
/
Humans
/
Male
Language:
En
Journal:
Int J Impot Res
Journal subject:
MEDICINA REPRODUTIVA
/
UROLOGIA
Year:
2006
Document type:
Article
Affiliation country:
United States